Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

Viveve Inc.250 enrolled

Overview

This study is evaluating the safety and efficacy of the Geneveve Treatment for women experiencing diminished sexual function following vaginal childbirth. Participants will be randomized to either active or sham treatment and followed for 12 months.

Decreased sensation and decreased sexual satisfaction following vaginal childbirth has the potential to negatively impact overall sexual function and quality of life in many women. Previous research by obstetricians and gynecologists (OB/GYNs) found that changes in sexual health post-childbirth are not often discussed between physicians and their patients. One possible reason these discussions are not being initiated by physicians is the lack of an evidence-based treatment other than surgery. While traditional surgery can be performed to improve sexual function following childbirth, pain at incision lines and scarring can lead to dyspareunia for months following the procedure, and a surgical procedure can be painful and the sutures may cause dense scarring. The post-operative recovery may last up to seven days before a woman can return to work. Resuming intercourse is not recommended for at least six weeks after these invasive surgeries. For the many women who are not good surgical candidates, due to health issues or situational limitations on downtime or their unwillingness to undergo a surgical procedure to improve sexual function, there is no other option. The Geneveve Treatment offers a simple alternative to traditional surgery using non-ablative radiofrequency (RF) energy as a non-surgical approach to improve sexual function following vaginal childbirth. It induces a mild, controlled reaction in the submucosal tissues that stimulates the body to deposit collagen, thereby remodeling the tissue without causing scarring. This study is designed to demonstrate that active treatment (i.e., Geneveve Treatment) is superior to the sham treatment for the primary efficacy and safety endpoints. The active treatment group will receive a treatment dose of 90 J/cm\^2 and the sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2. The participant, the investigator, and all study personnel will be blinded to the assignment for the entire study duration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

250

Conditions

Female Sexual Dysfunction

Interventions

Geneveve TreatmentDEVICE

The active treatment group will receive a treatment dose of 90 J/cm\^2

Sham TreatmentDEVICE

The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age at time of screening and pre-menopausal * At least one vaginal delivery (\> 37 completed weeks gestation) * Sexual dysfunction * Negative pregnancy test at Screening visit * Sexually active Exclusion Criteria: * Currently breastfeeding or recently discontinued breastfeeding * Medical history of keloid formation, genital fistula, thin recto-vaginal septum or obstetric trauma * Implantable electrical device * Medical or immunological condition * Chronic use of anti-inflammatory drugs * Current or previous use of local vaginal hormones * Undergone previous elective surgical or non-invasive procedure(s) at the vaginal introitus

Locations (21)

VIVEVE II Study Site

La Mesa, California, United States

VIVEVE II Study Site

Orange, California, United States

Outcomes

Primary Outcomes

Female Sexual Function Index (FSFI) Total Score

The FSFI is a 19-item validated measure of female sexual function. The FSFI consists of six domains: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain. The recall period is the past 4 weeks. Each item's score can range from 0-5 (or 1-5 in several instances). For individual domain scores, the scores of the individual items that comprise the domain are summed, and the sum is multiplied by the domain factor. The six domain scores are summed to obtain the full scale score. It should be noted that within the individual domains, a domain score of zero indicates that the subject reported having no sexual activity during the past month. The total score is the sum of the domain scores and ranges from 2-36.

Time frame: 6 months post-treatment

Secondary Outcomes

Incidence of Treatment-Emergent Adverse Events

Safety as reported through Adverse Events from the time the subject signs the consent form through study completion.

Time frame: 12 months post-treatment

Female Sexual Function Index (FSFI) Arousal Domain Score

The FSFI is a 19-item validated measure of female sexual function. The FSFI Arousal domain recall period is the past 4 weeks. Each item's score can range from 0-5 (or 1-5 in several instances). For individual domain scores, the scores of the individual items that comprise the domain are summed, and the sum is multiplied by the domain factor. It should be noted that within the individual domains, a domain score of zero indicates that the subject reported having no sexual activity during the past month.

Time frame: 6 months post-treatment

Female Sexual Function Index (FSFI) Orgasm Domain Score

The FSFI is a 19-item validated measure of female sexual function. The FSFI Orgasm domain recall period is the past 4 weeks. Each item's score can range from 0-5 (or 1-5 in several instances). For individual domain scores, the scores of the individual items that comprise the domain are summed, and the sum is multiplied by the domain factor. It should be noted that within the individual domains, a domain score of zero indicates that the subject reported having no sexual activity during the past month.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.